This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Qiangke

Simcere Pharmaceutical Group

Drug Names(s): Biosimilar Enbrel, etanercept, Recombinant Human TNF Receptor-IgG Fusion Protein for Injection

Description: Qiangke is a biosimilar version of etanercept (Enbrel).

Enbrel is a recombinant protein with properties of a monoclonal antibody. It is a fusion protein of the Fc (constant region) of a human antibody grafted to the ligand-binding portion of the human TNF receptor. The TNF receptor part of Enbrel functionally substitutes for an anti-TNF antibody. Blocking the activity of TNF impacts both autoimmunity and the immune response to pathogens.


Qiangke News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug